• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

马伐卡坦对主动脉瓣狭窄与梗阻性肥厚型心肌病这一具有挑战性的联合病症的有效性

Usefulness of Mavacamten in the Challenging Association of Aortic Stenosis and Obstructive Hypertrophic Cardiomyopathy.

作者信息

Vanhaecke Pierre, Bohbot Yohann, Di Lena Chloé, Hucleux Emilion, Yemmi Mokrane, Tribouilloy Chistophe

机构信息

Department of Cardiology, Amiens University Hospital, Amiens, France.

UR UPJV 7517, Jules Verne University of Picardie, Amiens, France.

出版信息

JACC Case Rep. 2024 Aug 7;29(15):102430. doi: 10.1016/j.jaccas.2024.102430.

DOI:10.1016/j.jaccas.2024.102430
PMID:39157569
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11328762/
Abstract

The association of aortic stenosis (AS) and obstructive hypertrophic cardiomyopathy raises questions about AS quantification, the management of left ventricular outflow tract obstruction, and AS treatment. Recently, mavacamten demonstrated its efficacy in reducing left ventricular outflow tract obstruction gradient. This case reports on mavacamten use in this challenging association.

摘要

主动脉狭窄（AS）与梗阻性肥厚型心肌病的关联引发了关于AS量化、左心室流出道梗阻的管理以及AS治疗等问题。最近，马伐卡坦证明了其在降低左心室流出道梗阻梯度方面的疗效。本病例报告了马伐卡坦在这种具有挑战性的关联中的应用情况。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/37b14ecc1653/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/8bbc63791980/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/3eb0df759bac/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/b6752398c8f3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/18e8c131fc6f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/782be27ddadc/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/37b14ecc1653/gr5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/8bbc63791980/ga1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/3eb0df759bac/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/b6752398c8f3/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/18e8c131fc6f/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/782be27ddadc/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c9ef/11328762/37b14ecc1653/gr5.jpg

相似文献

1
Usefulness of Mavacamten in the Challenging Association of Aortic Stenosis and Obstructive Hypertrophic Cardiomyopathy.马伐卡坦对主动脉瓣狭窄与梗阻性肥厚型心肌病这一具有挑战性的联合病症的有效性
JACC Case Rep. 2024 Aug 7;29(15):102430. doi: 10.1016/j.jaccas.2024.102430.
2
Eighteen-Month Real-World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population.在一个种族多样化的人群中使用 Mavacamten 治疗梗阻性肥厚型心肌病的 18 个月真实世界经验。
J Am Heart Assoc. 2024 Aug 6;13(15):e034069. doi: 10.1161/JAHA.123.034069. Epub 2024 Jul 31.
3
Mavacamten for Obstructive Hypertrophic Cardiomyopathy: Rationale for Clinically Guided Dose Titration to Optimize Individual Response.马卡丹特治疗梗阻性肥厚型心肌病：基于临床指导剂量滴定以优化个体反应的原理。
J Am Heart Assoc. 2024 Sep 3;13(17):e033767. doi: 10.1161/JAHA.124.033767. Epub 2024 Aug 29.
4
Undiagnosed hypertrophic obstructive cardiomyopathy during transcatheter aortic valve replacement: a case report.经导管主动脉瓣置换术中未诊断出的肥厚性梗阻性心肌病：一例报告
J Med Case Rep. 2018 Dec 18;12(1):372. doi: 10.1186/s13256-018-1904-8.
5
Left ventricular ejection hemodynamics before and after relief of outflow tract obstruction in patients with hypertrophic obstructive cardiomyopathy and valvular aortic stenosis.肥厚型梗阻性心肌病合并主动脉瓣狭窄患者流出道梗阻解除前后左心室射血动力学变化。
J Thorac Cardiovasc Surg. 2020 Mar;159(3):844-852.e1. doi: 10.1016/j.jtcvs.2019.03.071. Epub 2019 Apr 4.
6
High left ventricular outflow tract gradient: Aortic stenosis, obstructive hypertrophic cardiomyopathy or both?高左心室流出道梯度：主动脉瓣狭窄、梗阻性肥厚型心肌病还是两者皆有？
Rev Port Cardiol. 2015 May;34(5):357.e1-5. doi: 10.1016/j.repc.2014.10.007. Epub 2015 Apr 29.
7
Long-Term Safety and Efficacy of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Interim Results of the PIONEER-OLE Study.马卡丹特治疗有症状梗阻性肥厚型心肌病的长期安全性和疗效：PIONEER-OLE 研究的中期结果。
J Am Heart Assoc. 2024 Apr 16;13(8):e030607. doi: 10.1161/JAHA.123.030607. Epub 2024 Apr 9.
8
Dose-Blinded Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy: Outcomes Through 32 Weeks.接受室间隔减容治疗的梗阻性肥厚型心肌病患者的剂量盲法肌球蛋白抑制：32周的结果
Circulation. 2023 Mar 14;147(11):850-863. doi: 10.1161/CIRCULATIONAHA.122.062534. Epub 2022 Nov 6.
9
Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.玛伐卡坦：用于治疗有症状的肥厚性梗阻性心肌病的首款心脏肌球蛋白口服调节剂。
Heart Int. 2022 Oct 5;16(2):91-98. doi: 10.17925/HI.2022.16.2.91. eCollection 2022.
10
Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy.马卡丹特对梗阻性肥厚型心肌病有症状患者超声心动图特征的影响。
J Am Coll Cardiol. 2021 Dec 21;78(25):2518-2532. doi: 10.1016/j.jacc.2021.09.1381.

引用本文的文献

1
Mavacamten Cardiac Myosin Inhibitor: Clinical Applications and Future Perspectives.麦卡姆坦（Mavacamten）：一种心肌肌球蛋白抑制剂的临床应用及未来展望
Cureus. 2025 Apr 21;17(4):e82722. doi: 10.7759/cureus.82722. eCollection 2025 Apr.
2
When the heart becomes suicidal: a case report of severe left ventricular outflow tract obstruction following transcatheter aortic valve implantation.当心脏出现“自杀式”情况：一例经导管主动脉瓣植入术后严重左心室流出道梗阻的病例报告
Eur Heart J Case Rep. 2025 May 7;9(5):ytaf164. doi: 10.1093/ehjcr/ytaf164. eCollection 2025 May.

本文引用的文献

1
Recommendations for Multimodality Cardiovascular Imaging of Patients with Hypertrophic Cardiomyopathy: An Update from the American Society of Echocardiography, in Collaboration with the American Society of Nuclear Cardiology, the Society for Cardiovascular Magnetic Resonance, and the Society of Cardiovascular Computed Tomography.肥厚型心肌病患者多模态心血管成像建议：美国超声心动图学会的更新，与美国核医学学会、心血管磁共振学会和心血管计算机断层成像学会合作。
J Am Soc Echocardiogr. 2022 Jun;35(6):533-569. doi: 10.1016/j.echo.2022.03.012.
2
Outcomes in Patients With Obstructive Hypertrophic Cardiomyopathy and Concomitant Aortic Stenosis Undergoing Surgical Myectomy and Aortic Valve Replacement.梗阻性肥厚型心肌病合并主动脉瓣狭窄患者行心肌切除术和主动脉瓣置换术的结果。
J Am Heart Assoc. 2021 Sep 21;10(18):e018435. doi: 10.1161/JAHA.120.018435. Epub 2021 Sep 17.
3
2021 ESC/EACTS Guidelines for the management of valvular heart disease.2021年欧洲心脏病学会/欧洲心胸外科学会瓣膜性心脏病管理指南。
Eur Heart J. 2022 Feb 12;43(7):561-632. doi: 10.1093/eurheartj/ehab395.
4
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.马卡丹特治疗有症状梗阻性肥厚型心肌病（EXPLORER-HCM）的随机、双盲、安慰剂对照、3 期临床试验
Lancet. 2020 Sep 12;396(10253):759-769. doi: 10.1016/S0140-6736(20)31792-X. Epub 2020 Aug 29.
5
Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement.肥厚型梗阻性心肌病患者行经导管主动脉瓣置换术的预后分析。
JAMA Netw Open. 2020 Feb 5;3(2):e1921669. doi: 10.1001/jamanetworkopen.2019.21669.
6
Aortic Stenosis With Severe Asymmetric Septal Hypertrophy: A Novel Management Strategy to Improve TAVR Outcomes.伴有严重不对称性室间隔肥厚的主动脉瓣狭窄：一种改善经导管主动脉瓣置换术（TAVR）结局的新型管理策略。
JACC Cardiovasc Interv. 2019 Nov 11;12(21):2228-2230. doi: 10.1016/j.jcin.2019.06.025.